Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
What makes Wayve stand out is that its autonomous vehicle software is designed to learn to drive while driving, sort of like humans do.
A slew of retail company earnings reports last week raised the spectre of sapped spending as executives discussed tariffs.
Tesla’s stock closed down for a record seventh consecutive week on Friday, and has nearly erased a $700 billion post-election rally.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Microgrids could offer a stopgap solution until small modular reactors are ready for the market.
Novo Nordisk will sell its blockbuster weight-loss drug Wegovy for under half its normal price via a new direct-to-consumer online pharmacy.
Policies floated by European Union leaders that could boost the bloc’s defense spending have sent the company’s shares flying.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
The titanic port deal immediately made political waves, even as the seller, conglomerate CK Hutchison, denied politics were at play.
Here’s the bad news: Auto manufacturing is a notoriously thin-margin industry, and tariffs could tear right through those margins.
The biggest restaurant chain in the world just completed a splashy IPO — and you’ve likely never heard of it.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.